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Abstract
Anti-RNA polymerase III (RNAP III) antibodies are highly specific for scleroderma (SSc) and
associated with diffuse SSc and renal crisis. Coexistence of anti-RNAP III and other SSc
autoantibodies is rarely documented. We report three cases with coexisting anti-RNAP III and
anti-U1RNP. Autoantibodies in 3829 sera from rheumatology clinics were screened by
immunoprecipitation. Anti-RNAP III-positive sera were also examined by immunofluorescence
and anti-RNAP III ELISA. In total, 35 anti-RNAP III-positive sera were identified by
immunoprecipitation, in which three had coexisting anti-U1RNP. All three were anti-RNAP III
ELISA positive. Two had anti-RNAP I dominant (vs. RNAP III) reactivity and showed strong
nucleolar staining. A case with anti-U1/U2RNP (U2RNP dominant) had systemic lupus
erythematosus (SLE)–SSc overlap syndrome; however, the remaining two cases had SLE without
signs of SSc. All three cases of anti-RNAP III + U1RNP fulfilled ACR SLE criteria but none in
the group with anti-RNAP III alone (p = 0.0002). In contrast, only one case in the former group
had sclerodermatous skin changes and Raynaud’s phenomenon, vs. 92% with scleroderma in the
latter (p < 0.05). Although anti-RNAP III is highly specific for SSc, cases with coexisting anti-
U1RNP are not so uncommon among anti-RNAP III positives (8%, 3/35) and may be SLE without
features of SSc.
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Introduction
Several autoantibodies, such as anti-topoisomerase I (topo I), anti-RNA polymerase III
(RNAP III), anti-centromere (ACA), anti-U3RNP/fibrillarin, anti-Th/To, anti-PM-Scl, and
anti-U1RNP are associated with a diagnosis of scleroderma (systemic sclerosis, SSc).
Among them, anti-topo I and anti-RNAP III antibodies are considered highly specific for
SSc, and their detection in other diseases verified by reliable methods is rare.1–3 Each of
these autoantibodies is associated with a unique clinical subset of SSc: anti-topo I, RNAP
III, and U3RNP are associated with diffuse SSc; ACA and anti-Th/To with limited SSc; and
anti-PM-Scl and anti-U1RNP with SSc overlap syndrome. In addition, SSc-related
autoantibodies are linked with particular clinical manifestations, such as anti-topo I with
severe interstitial lung disease (ILD), and anti-RNAP III with scleroderma renal crisis.1,2 An
interesting yet unexplained characteristic that allows relatively clean clinical subsetting and
analysis based on autoantibody specificity in SSc is the rare coexistence of more than one
SSc-related autoantibody specificity.1
Anti-RNAP I/III was described as a disease marker of SSc over 20 years ago; however,
immunoprecipitation (IP) has been the only method to test this specificity until several years
ago when commercial enzyme-linked immunosorbent assay (ELISA) kits became widely
available.2,3 Although coexistence of anti-RNAP III and other SSc-related autoantibodies is
reported more frequently by ELISA,4–8 cases verified by IP are rarely described. We here
report three cases of anti-RNAP III coexisting with anti-U1RNP verified by IP, two of them
without any signs of SSc.
Patients and methods
Patients
All 1966 subjects enrolled in the University of Florida Center for Autoimmune Diseases
(UFCAD) registry from 2000–2010 were studied. Diagnoses of the patients include 434
cases of systemic lupus erythematosus (SLE), 119 SSc, 85 cases of polymyositis/
dermatomyositis (PM/DM), and various other diagnoses. In addition, 1466 sera (including
208 SLE) from University of North Carolina Hospitals, 149 (62 SLE, 67 PM/DM, 20
Sjögren’s syndrome) from University of Guadalajara, 248 sera (26 PM/DM, 57 SSc, 113
SLE, and 52 primary anti-phospholipid syndrome) from Spedali Civili di Brescia (Brescia,
Italy) were also screened for autoantibodies. The total number of SLE sera tested was 817.
Clinical information was from the database (patients from University of Florida and
University of North Carolina) or charts (all institutes). The protocol was approved by the
Institutional Review Board. This study meets and is in compliance with all ethical standards
in medicine, and informed consent was obtained from all patients according to the
Declaration of Helsinki.
Immunoprecipitation
Autoantibodies in sera from patients were screened by IP using 35S-methionine-labeled
K562 cell extracts. Anti-RNAP III, anti-U1RNP and other autoantibodies were determined
using reference sera.9,10 Analysis of RNA components of immunoprecipitates was by urea-
PAGE and silver staining (Bio-Rad Laboratories, Inc., Hercules, CA, USA).11
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Immunofluorescence antinuclear antibodies
Immunofluorescence antinuclear (ANA)/cytoplasmic antibodies (HEp-2 ANA slides;
INOVA Diagnostics, San Diego, CA, USA) were tested using a 1:80-diluted human serum
and DyLight488 donkey IgG F(ab)’2 anti-human IgG (gamma chain specific, 1:200 dilution;
Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA).12
ELISA
Sera were tested for IgG anti-RNAP III antibodies using a commercial ELISA kit
(QUANTA Lite® RNA Pol III, INOVA Diagnostics, San Diego, CA, USA) following the
manufacturer’s instruction.
Statistical analysis
Data between groups were compared by Fisher’s exact test (frequency) or Mann–Whitney
test (levels) using Prism 5.0 for Macintosh (GraphPad Software, Inc., San Diego, CA, USA);
p < 0.05 was considered significant.
Results
Autoantibodies to RNA polymerase I/III were detected by IP in 21 patients from UFCAD,
11 from North Carolina, one from Guadalajara, and two from Brescia. Virtually all sera with
anti-RNAP III also had anti-RNAP I, and usually the intensity of RNAP III was dominant,
or RNAP I and III were similar.13,14 Three of 35 anti-RNAP III sera (8%) had coexisting
anti-U1RNP, including one that had predominant anti-U2RNP reactivity (Figure 1A).
Intensity of RNAP I in IP appeared to be stronger than that of RNAP III in cases 1 and 2 (I >
III, Table 1), different from the pattern of the majority of patients with SSc,14 but consistent
with strong nucleolar staining in these sera (Figure 1B, panels 1 and 2). Intensity of RNAP I
and III was comparable in case 3 (I = III, Table 1), and positive nucleolar staining of this
serum was less clear when the nuclear staining was strong (Figure 1B, panel 3); this is
consistent with similar observations described for many anti-RNAP I/III-positive SSc
patients not reported to be nucleolar positive in routine clinical laboratories.15 In any case,
these results are consistent with known distributions of RNAPs; RNAP III and II localize to
the nuclei, whereas RNAP I localizes to nucleoli.16,17 Levels of anti-RNAP III were tested
by ELISA, comparing cases with anti-RNAP III + U1RNP vs. anti-RNAP III-positive SSc
(Figure 1C). All three in the former group were anti-RNAP III ELISA positive, and their
levels were not lower than those in the latter. The presence of anti-U1RNP antibodies by IP
is shown in Figure 1D. A serum sample from case 1 immunoprecipitated U1 and U2snRNP
(Figure 1D and 1E) with unusual U2RNP dominant reactivity,18,19 as shown in protein IP
(Figure 1D) and analysis of immunoprecipitated RNA components using a small amount
(0.5 μl) of serum (Figure 1E, lane).
Clinical features of the three interesting cases of coexisting anti-RNAP III and anti-U1RNP
are summarized in Table 1. Case 1 is a 66-year-old Caucasian female who developed
Raynaud’s phenomenon and skin tightening in 1982 and was diagnosed with CREST
syndrome. Later, during the 1990s she developed deforming arthritis and sicca symptoms,
and also had a diagnosis of hypothyroidism. She was admitted to a hospital in June 2006 for
chest pain thought to be due to pleuropericarditis with a pericardial effusion, and was
referred to the UFCAD. Sclerodactyly, digital pitting scars, flexion contracture and
subluxation of metacarpophalangeal and proximal interphalangeal joints, ulnar deviation,
subcutaneous calcinosis, teleangiectasia, and ILD, were noted. ANA (speckled pattern, titer
> 1: 1280), anti-dsDNA (Crithidia, 1: 20) and anti-RNAPI/III were positive. She was
classified as having a SSc–SLE overlap syndrome.
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Case 2 was included in the previous study on anti-RNAP II autoantibodies in SLE and SLE
overlap syndrome.9 This patient already had SLE at the initial visit, and six sequential sera
over a 4-year period were tested by IP and anti-RNAP III ELISA. IP patterns were nearly
identical in all sera. The anti-RNAP III ELISA units did not change significantly, fluctuating
between 43 and 63 units (data not shown). No Raynaud’s phenomenon or sclerodermatous
features were noted during the 4-year observation.
Case 3 is a Mexican female with a long history of SLE. She developed thrombocytopenia in
May 1982 at age 22 during her first pregnancy, and also had discoid rash and leukopenia.
She developed autoimmune hemolytic anemia during her second pregnancy in 1983, and
ANA and anti-Sm antibodies were detected. A diagnosis of SLE was made and she was
treated with prednisone and hydroxychloroquine. During 1990s she had flares of SLE with
thrombocytopenia and hemolytic anemia, discoid rash, polyarthritis, nephrotic syndrome,
and chronic renal failure. She was treated with prednisone and azathioprine, followed by
cyclophosphamide from 1994 to 2010. No Raynaud’s phenomenon or scleroderma features
were noted during observation.
Clinical features of the three cases of anti-RNAP III + anti-U1RNP were compared with
those in patients with anti-RNAP III alone (Table 2). All three cases in the former group
fulfilled American College of Rheumatology criteria of SLE, but none in the latter group (p
= 0.0002). In contrast, only one case in the former group had sclerodermatous skin changes
or Raynaud’s phenomenon (p < 0.05).
Discussion
To date, detection of anti-RNAP III in patients with a diagnosis other than SSc is
uncommon.1 Most previous studies did not find any positives in non-SSc systemic
autoimmune rheumatic diseases by IP.6,13,20 One study reported anti-RNAP III in one of
138 patients with SLE (case 2 in Table 1).9 Only one of 434 SLE patients from UFCAD
(case 1, SLE–SSc overlap syndrome) and one of 62 Mexican patients with SLE (case 3)
were positive in the present study. Although anti-RNAP III ELISA is a reliable test, there
have been more positives in patients other than SSc reported, but prevalence is usually less
than a few percent.4,6,21 Positives in non-SSc patients were usually only weakly
positive;5,6,21 many of them were negative by IP and considered false-positive results
caused by reactivity with contaminating bacterial components.6,21
Mutual exclusiveness of SSc-related autoantibodies in each patient is well described.1–3
Most studies using IP confirmed the absence of coexistence of anti-RNAP III with other
SSc-related autoantibodies.5,13,22 A case of SLE with the coexistence of anti-RNAP I/II/III
with anti-U1RNP and Ku antibodies by IP, reported previously,9 is included in the present
study as case 2. In studies using anti-RNAP III ELISA, the coexistence of other SSc-related
autoantibodies has been reported more frequently.4–8 However, many cases in this category
had only low levels of reactivity,7 and at least some were confirmed to be IP negative,5
suggesting that many of these may not be true cases of coexistence. Alternatively, it is
possible that patients with low levels of anti-RNAP III tend to have coexisting SSc-related
autoantibodies. Thus, although anti-RNAP III ELISA is a clinically useful assay, false
positives still occur as discussed above. In cases of anti-RNAP III ELISA positives with a
diagnosis other than SSc or coexistence of other SSc-related autoantibodies, in particular at
low levels of reactivity, cautious interpretation is advised and confirmation by IP would be
ideal.
The two patients with anti-RNAP III without signs of SSc in this study were somewhat
surprising, considering the high disease specificity of anti-RNAP III. When anti-RNAP III
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developed in these patients, or how many years anti-RNAP III can precede the clinical
manifestation of SSc, is unknown. Nevertheless, these patients were observed for several
years after confirmation of the presence of anti-RNAP III. It is interesting to speculate that
presence of anti-U1RNP antibodies affects the disease phenotype or progression. For
example, TLR stimulation of type I IFN production by the anti-U1RNP-UsnRNPs immune
complex23,24 may create an environment that is not optimal for the expression of the anti-
RNAP III-related disease phenotype. It is also possible that the proper environment for anti-
U1RNP production may be incompatible with development of anti-RNAP III-associated SSc
features. This situation could be somewhat similar to different autoantibody production in
animal models of SLE, in which NZB/NZW F1 mice produce anti-RNA helicase A vs. anti-
snRNPs,25 or SJL/J mice produce anti-fibrillarin (U3RNP) vs. anti-ribosomal P antibodies,26
depending on different environments, as we reported. Another possibility is the potential
effects of treatment for SLE, such as high-dose steroid and immunosuppressive therapy,
which might have prevented the development of SSc-related features.
The clinical significance of anti-RNAP III detected in SLE patients is, of course, not known.
Patients with anti-RNAP III can present without sclerodermatous skin changes but with
internal organ involvement consistent with SSc, known as systemic sclerosis sine
sclerodema.27–29 A patient with SLE with anti-RNAP III antibodies who developed renal
crisis and was considered a SLE–sine scleroderma overlap syndrome has been described,30
suggesting that patients with SLE who develop acute renal failure may benefit from testing
for anti-RNAP III antibodies. In some cases, internal organ involvement such as renal or
lung disease may precede skin manifestation of SSc, and the detection of anti-RNAP III will
provide useful diagnostic and prognostic information.
Anti-RNAP III antibodies confirmed by IP analysis in SLE are rare and found only in 0.3%
of cases, based on our experience. It is estimated that around 1% of cases of anti-U1RNP-
positive SLE also have anti-RNAP III. Although coexistence of anti-RNAP III and -U1RNP
has been rarely reported, our data of 3/35 (8%) of anti-RNAP III-positive patients with
coexisting anti-U1RNP suggest that it is not so uncommon. When anti-U1RNP antibodies
are detected in patients, testing for anti-RNAP III antibodies is not always considered, but
the present data suggest that careful evaluation of anti-RNAP III is necessary in SLE
patients with anti-U1RNP.
In summary, we report three cases of coexisting anti-RNAP III and anti-U1RNP antibodies,
one with SLE–SSc overlap syndrome and two cases with SLE without signs of SSc. Since
anti-RNAP III-positive patients can develop life-threatening SSc internal organ
involvement, the significance of anti-RNAP III in SLE will need to be evaluated carefully.
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Figure 1. Anti-RNA polymerases and UsnRNPs autoantibodies
A. 8% SDS-PAGE analysis of immunoprecipitation resolving the high molecular weight
components of RNAPs. 35S-methionine-labeled K562 cell extract was immunoprecipitated
by serum samples from patients with anti-RNA polymerases and anti-U1RNP and controls.
Samples were analyzed by 8% SDS-PAGE. Lane I, II, III, anti-RNAP I/II/III; I ,III, anti-
RNAP I/III; lanes 1–3, cases 1–3 with anti-RNAP III and -U1RNP as listed in Table 1; Sm,
anti-Sm; NOR90, anti-NOR90, NHS, normal human serum. The positions of the two largest
subunits of RNA polymerase I, II, and III, components of U1 and U2 snRNPs, and
molecular weight markers are indicated. Arrowheads indicate NOR90, Ku (p70/p80), and
RNA helicase A in lanes 1–3, respectively. B. Immunofluorescence. HEp-2 ANA slide was
stained with sera from cases 1 – 3 and normal human serum (NHS) at 1:80 dilutions. C.
Anti-RNAP III levels by ELISA. Sera from the three cases with anti-RNAP III and -U1RNP
vs. anti-RNAP III alone (n=19) were tested by ELISA. Cut-off (<20 units) is shown by
shaded area. D. 12.5% SDS-PAGE analysis of the U1RNP components. Immunoprecipitated
samples by sera with anti-RNAP III and -U1RNP (1–3) and controls were analyzed by
12.5% SDS-PAGE. Positions of components of U1RNP (left) and U2-B” (white arrowhead)
and molecular weight markers are indicated. U1, Sm, U2, prototype human serum for anti-
U1RNP, Sm, and U2RNP, respectively; NHS, normal human serum; 0.5μl, 8μl, amount of
serum used for immunoprecipitation. E. Analysis of immunoprecipitated RNA components.
RNA components immunoprecipitated by sera were analyzed by urea-PAGE and silver
staining. Total, total RNA; U1RNP, Sm, U2RNP, prototype human sera for each specificity.
Positions of U1, 2, 4, 5, and 6 snRNA are shown.
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Table 1
Three cases with anti-RNA polymerase III and -U1RNP antibodies
Case 1 2 3
Anti-RNAP I, II, III I, II, III I, II, III
I>III=II I>II>>>III I=III>II
Anti-RNAPIII ELISA (>20 U, positive) 49 U 43-63 U 103 U
Coexisting antibodies U1/U2RNP (U2>U1) U1RNP U1RNP
NOR90 Ku RHA
Diagnosis SLE–SSc SLE SLE
Race/gender Caucasian/F African Am/F Mexican/F
Age (onset/last visit) 42/66 38/42 22/50
Observation (after anti-RNAP III) (years) 2 4 5
Proximal scleroderma − − −
Sclerodactyly + − -
Pitting scar + − −
ILD + − −
Raynaud’s phenomenon + − −
SLE criteria Arthritis Discoid Photosensitivity
Serositis Arthritis Arthritis, Nephritis
Anti-dsDNA Serositis Thrombocytopenia
ANA Hematologic AIHA, Leukopenia
Anti-dsDNA, ANA Anti-Sm, ANA
Other Sjogren’s syndrome
Hypothyroidism
RNAP, RNA polymerases; RHA, RNA helicase A; F, female; ANA, antinuclear antibodies; AIHA, autoimmune hemolytic anemia.
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Table 2
Clinical features of patients with anti-RNAP III+anti-U1RNP vs. anti-RNAP III
Anti-RNAP III+U1RNP Anti-RNAP III
n 3 32
SLE (ACR criteria) 100%a 0%a
Overlap syndrome 33% 0%
Scleroderma (ACR criteria) 33%b,c 91%b (−97%c)
Diffuse cutaneous scleroderma 0%d 77%d
Any sclerodermatous changes (sclerodactyly or proximal scleroderma) 33%e 91%e
Raynaud’s phenomenon 33%f 86%f
Anti-RNAP III ELISA positive 100% 84%
ap=0.0002.
bp=0.0474.
cp=0.0148; includes a case that can be considered systemic sclerosis sine scleroderma (one with ILD, one with Raynaud’s phenomenon, dilated
cardiomyopathy and an episode consistent with scleroderma renal crisis).
dp=0.0243; the number in anti-RNAP III groups is 17/22 due to availability of charts for review.
ep=0.0474.
fp=0.0913; the number in anti-RNAP III group is 19/22.
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